Compare PAYP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | NBIX |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 13.9B |
| IPO Year | 2026 | 1996 |
| Metric | PAYP | NBIX |
|---|---|---|
| Price | $20.43 | $129.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 22 |
| Target Price | $22.90 | ★ $175.27 |
| AVG Volume (30 Days) | ★ 4.6M | 868.5K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | N/A | $22.85 |
| Revenue Next Year | N/A | $9.99 |
| P/E Ratio | ★ N/A | $27.99 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $17.80 | $84.23 |
| 52 Week High | $21.76 | $160.18 |
| Indicator | PAYP | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.03 |
| Support Level | N/A | $128.03 |
| Resistance Level | N/A | $136.74 |
| Average True Range (ATR) | 0.00 | 2.95 |
| MACD | 0.00 | 0.30 |
| Stochastic Oscillator | 0.00 | 35.47 |
PayPay Corp is a Japan-based financial technology provider operating a digital finance platform that integrates payments, banking, credit, and investment services for individuals and businesses. Its platform connects users and merchants, facilitating a cashless ecosystem and providing an all-in-one solution for daily financial activities. The company operates in two reportable segments: i) Payment segment and ii) Financial service segment. The majority of the company's revenue is derived from the Financial service segment, which includes internet banking services, securities intermediary services and PayPay Point investment-related services, and loan management services. Geographically, it operates predominantly in Japan.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.